Results 81 to 90 of about 27,758 (263)

Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T-cell lymphoma

bioRxiv, 2022
Peripheral T cell lymphoma (PTCL) is a heterogeneous group of hematological cancers arising from the malignant transformation of mature T cells. In a cohort of 28 PTCL cases, we identified recurrent overexpression of MYCN, a member of the MYC family of ...
Marlies Vanden Bempt, K. Debackere, S. Demeyer, Q. Van Thillo, N. Meeuws, C. Prieto, S. Provost, N. Mentens, K. Jacobs, O. Gielen, D. Nittner, S. Ogawa, K. Kataoka, C. Graux, T. Tousseyn, J. Cools, D. Dierickx   +16 more
semanticscholar   +1 more source

Inhibition of OCT4 binding at the MYCN locus induces neuroblastoma cell death accompanied by downregulation of transcripts with high-open reading frame dominance

Frontiers in Oncology
Amplification of MYCN is observed in high-risk neuroblastomas (NBs) and is associated with a poor prognosis. MYCN expression is directly regulated by multiple transcription factors, including OCT4, MYCN, CTCF, and p53 in NB.
Kazuma Nakatani, Kazuma Nakatani, Kazuma Nakatani, Kazuma Nakatani, Hiroyuki Kogashi, Hiroyuki Kogashi, Takanori Miyamoto, Taiki Setoguchi, Tetsushi Sakuma, Kazuto Kugou, Yoshinori Hasegawa, Takashi Yamamoto, Yoshitaka Hippo, Yoshitaka Hippo, Yoshitaka Hippo, Yusuke Suenaga   +15 more
doaj   +1 more source

DREAM target reactivation by core transcriptional regulators supports neuroblastoma growth

Molecular & Cellular Oncology, 2019
Chromosome 17q gains are a common alteration in high-risk neuroblastomas with unknown functional significance. We identified a 17q super-enhancer regulated T-box Transcription Factor 2 (TBX2) as constituent of a core regulatory circuitry driving ...
Bieke Decaesteker, Katleen De Preter, Frank Speleman   +2 more
doaj   +1 more source

Prognostic significance of MYCN related genes in pediatric neuroblastoma: a study based on TARGET and GEO datasets

BMC Pediatrics, 2020
Background Neuroblastoma patients with MYCN amplification are associated with poor prognosis. However, the prognostic relevance of MYCN associated genes in neuroblastoma is unclear. Methods The expression profiles of MYCN associated genes were identified
Haiwei Wang, Xinrui Wang, Liangpu Xu, Ji Zhang, Hua Cao   +4 more
doaj   +1 more source

CKLF instigates a “cold” microenvironment to promote MYCN-mediated tumor aggressiveness

Science Advances
Solid tumors, especially those with aberrant MYCN activation, often harbor an immunosuppressive microenvironment to fuel malignant growth and trigger treatment resistance.
Xiao-Dan Qin, Andrew Lam, Xu Zhang, Satyaki Sengupta, J. B. Iorgulescu, Hongru Ni, Sanjukta Das, Madison Rager, Zhenwei Zhou, Tao Zuo, Grace K. Meara, Alexander Floru, C. Kemet, D. Veerapaneni, Daniel Kashy, Liang Lin, Kenneth Lloyd, Lauren Kwok, Kaylee S. Smith, R. Nagaraju, R. Meijers, C. Ceol, Ching-Ti Liu, S. Alexandrescu, Catherine J. Wu, Derin B. Keskin, Rani E. George, Hui Feng   +27 more
semanticscholar   +1 more source

MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma

Nature Communications, 2022
Neuroblastoma (NB) is a childhood cancer arising from sympatho-adrenal neural crest cells. MYCN amplification is found in half of high-risk NB patients; however, no available therapies directly target MYCN.
Ling Tao, Mahmoud A. Mohammad, G. Milazzo, Myrthala Moreno-Smith, Tajhal D. Patel, B. Zorman, Andrew A. Badachhape, Blanca E. Hernandez, Amber B. Wolf, Zi-Hua Zeng, Jennifer H. Foster, S. Aloisi, Pavel Sumazin, You-Li Zu, John Hicks, K. B. Ghaghada, N. Putluri, Giovanni Perini, C. Coarfa, Eveline Barbieri   +19 more
semanticscholar   +1 more source

Lorlatinib‐Containing Therapy for MYCN‐Amplified, ALK‐Mutated Neuroblastoma With Bulky Leptomeningeal Relapse: A Case Report

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Central nervous system (CNS) relapse of neuroblastoma carries a poor prognosis, and craniospinal irradiation (CSI) poses substantial long‐term toxicity in young children. We report a toddler with MYCN‐amplified neuroblastoma harboring somatic ALK R1275Q who developed extensive leptomeningeal relapse with paraplegia.
Jinwoo Kim, Minji Kim, Nani Jung, Sung Eun Kim, Ji Yoon Kim, Mi Ae Chu, Jung Eun Kwon, Yeo Hyang Kim, So Mi Lee, Ki‐Su Park, Jeong Eun Lee, Ye Jee Shim   +11 more
wiley   +1 more source

Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas

International Journal of Oncology, 2010
Neuroblastoma is a childhood malignancy of the sympathetic nervous system. The tumor exhibits two different phenotypes: favorable and unfavorable. MYCN amplification is associated with rapid tumor progression and the worst neuroblastoma disease outcome.
Jaime, Torres, Paul L, Regan, Robby, Edo, Payton, Leonhardt, Eric I, Jeng, Eric F, Rappaport, Naohiko, Ikegaki, Xao X, Tang   +7 more
openaire   +3 more sources

High-Level MYCN-Amplified RB1-Proficient Retinoblastoma Tumors Retain Distinct Molecular Signatures

Ophthalmology Science, 2022
Purpose Retinoblastomas are malignant eye tumors diagnosed in young children. Most retinoblastomas are genetically characterized by biallelic inactivation of the RB1 gene. However, 1.5% of tumors demonstrate high-level amplification of the proto-oncogene
Khashayar Roohollahi, Y. de Jong, S. V. van Mil, A. Fabius, A. Moll, J. Dorsman   +5 more
semanticscholar   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source